Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Bullboard (GREY:IMVIF)

View:
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
Comment by qwerty22on Mar 18, 2021 4:03pm

RE:DLBCL trial

Effectively almost all oncology approvals of new molecules are accelerated approval because they are based on surrogate endpoints. The question to ask is whether they see the 2b as being ...more  
276
Discussion
Post by Biotech010on Mar 18, 2021 3:21pm

DLBCL trial

I spoke to the company yesterday. Doing a phase 2b does not preclude an accelerated approval.  In the first part they want to repeat the data they had in the PDL-1 positive population in a ...more  
289
Discussion
Post by Jthom376on Mar 18, 2021 1:54pm

ATM IMV

I came across the following. Thought it was interesting. Never have seen who the big buyer was from JAN In addition, the Corporation entered into the October 2020 ATM allowing the Corporation to ...more  
279
Comment by LR6852on Mar 17, 2021 8:34pm

RE:What’s the deal with the new drug name?

This is what Fred said this morning: "I am really proud today to share with you the generic name of our first product, Maveropepimut-S, formerly known as DPX-Survivac, not only this new name ...more  
273
Discussion
Post by alphaseeking001on Mar 17, 2021 8:21pm

What’s the deal with the new drug name?

Silly question.  Any explanation as to why IMV is now calling their former DPX-Survivac product by the name "maveropepimut-S".  What the heck is with the change... even harder to ...more  
254
Discussion
Comment by qwerty22on Mar 17, 2021 5:25pm

RE:RE:Capitulation

That's certainly the point Fred was trying to make but again solid numbers would tell that story better than long winded statements.  
194
Discussion
Comment by Breakthoroughon Mar 17, 2021 5:20pm

RE:RE:RE:RE:RE:RE:If the tree falls in the forest...

True. Not to share (at least) the threshold leads to supect that the numbers are not so great. The point is that this contradicts thr "making a big difference" mention. May be it also has to ...more  
173
Discussion
Comment by qwerty22on Mar 17, 2021 5:08pm

RE:RE:RE:RE:RE:If the tree falls in the forest...

Do you not think that instead of that ramble if he had just said what the ORR in each of those indications was and what the thresholds were we would have known exactly what to think? If they really ...more  
181
Discussion
Comment by LR6852on Mar 17, 2021 5:06pm

RE:Capitulation

Monotherapy for ovarian still viable just not with keytruda.
128
Discussion
Post by europe10on Mar 17, 2021 4:06pm

Capitulation

Today, Was a day of capitulation Still some capitulation to do for those that invested for COVID-19 vaccine But "HOUSTON WE GOT A PROBLEM" When investing there are 3 important parameters 1 ...more  
271
Discussion
Post by TexasTea20on Mar 17, 2021 2:58pm

Well Folks...

Agree with the management commentary for the most part. I added today for the first time in a long-time because I believe we are now at the beginning. DLBCL partnering/licensing next up by end of Q1 ...more  
245
Post by gardyon Mar 17, 2021 2:55pm

No hurry!!

You would be in no hurry too, if you were pulling in the salaries this management team is recieving. Gardy
136
Comment by Breakthoroughon Mar 17, 2021 2:44pm

RE:RE:RE:RE:If the tree falls in the forest...

And also to this one. It says the PDL-1 expression (potential biomarker as in Linfoma) has to be explored in NSCLC patients. May be there is still room for a different trial in NSCLC, we cannot know ...more  
142
Discussion
Comment by Breakthoroughon Mar 17, 2021 2:41pm

RE:RE:RE:RE:If the tree falls in the forest...

The response to this question is interesting. It talks about pssible combinations and, also, uses the expresion "making a big difference" for the combination with Pembro not only in DLBCL ...more  
182
Discussion
Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities